Recordati : RECORDATI S'IMPLANTE SUR LE MARCHÉ ROUMAIN
09/06/2010 | 10:20 RECORDATI S′IMPLANTE SUR LE MARCHÉ ROUMAIN
Milan, le 8 juin 2010 - Recordati a annoncé l′acquisition d′ArtMed International, une société spécialisée dans la promotion de produits pharmaceutiques en Roumanie, qui dispose de bureaux à Bucarest. Dans le même temps, Recordati a également acquis les droits des produits dont ArtMed assure actuellement la promotion. Le prix de la transaction est de 1,2 million EUR, assorti d′une clause de complément (" earn-out ") basée sur le bénéfice net des 5 produits sous licence.
ArtMed est présente sur le marché pharmaceutique roumain depuis 2005 où elle a été une des premières sociétés indépendantes à offrir sur l′ensemble du territoire national des services intégrés de promotion et de commercialisation de médicaments sur ordonnance et de produits en vente libre. ArtMed has a staff of 24 employees dedicated to marketing and medical information activities directed at physicians and pharmacists. The medicines which are currently promoted are indicated prevalently for disorders resulting from nutrition deficiencies in addition to Revada® (diosmin) which is prescribed for venous insufficiency and other indications.
Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati′s current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2009 was E 747.5 million, operating income was E 162.2 million and net income was E 110.6 million.
Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company′s control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company′s activities and are not intended to indicate the advisability of administering any product in any particular instance.
Copyright Hugin
Ce communiqué de presse est diffusé par Hugin. L′émetteur est seul responsable du contenu de ce communiqué.
bourse
